1. Introduction {#s0005}
===============

Sphingolipids are comprised of glycosphingolipids, sphingomyelins, and free ceramides. In plants, free ceramides, which we refer to as ceramides herein, occur in low abundance when compared to other sphingolipids such as glucosylceramide (GlcCer) and sphingomyelin, which are enriched in plants. Food sphingolipids such as GlcCer, which is found in cereals, have been reported to be able to benefit health by preventing metabolic syndrome and related diseases. Konjac (*Amorphophallus konjac,* K. Koch) is a food plant that is rich in GlcCer. The efficacy of konjac GlcCer (kGlcCer) in trans-epidermal water loss in mice and humans has been studied by Uchiyama et al. [@bib1] and used as a health food and in cosmetics. However, it remains to be elucidated whether kGlcCer and its metabolites have a direct effect on itching hypersensitivity of skin by undesired extra-neurite invasions into the stratum corneum, which is often seen in itch-causing skin diseases such as atopic eczema and *Psoriasis vulgaris*. Recently, we have been successful in chemoenzymatically preparing konjac ceramide (kCer) by deglucosylation of kGlcCer. This prepared kCer possesses a neurite-outgrowth inhibitory effect that is absent in kGlcCer and other animal-type ceramides. This inhibitory activity by kCer is very similar to that of semaphorin3A (Sema3A), which induces CRMP2 phosphorylation [@bib2].

Sema3A is a repulsive factor for neuronal outgrowth of peripheral neurons and works opposite to nerve growth factor (NGF) in the stratum corneum in human healthy skin. The balance or ratio of activity of extracellular levels of Sema3A and NGF regulates skin barrier maintenance, preventing sensory nerves from extending neurites, which results in skin-hypersensitivity.

We were interested in examining the effect of kCer in keratinocytes, because they also express the Sema3A receptor, neuropilin1 (Nrp1), and kCer can bind Nrp1 in neurons. It has been reported that Sema3A suppresses cell migration of HaCaT cells, a human keratinocyte cell line, against serum-derived chemoattractants ([Fig. S1A](#s0080){ref-type="sec"}). This effect is due to activation of the Sema3A signaling pathway.

Histamine (His) stress has been shown to enhance immature keratinocyte migration [@bib3]. In this study, we examined whether kCer can inhibit that enhanced migration similarly to Sema3A.

His plays important roles in inflammation and nervous irritability in allergic disorders, including atopic dermatitis. His has been shown to regulate the expression of pruritic factors such as NGF and Sema3A in skin keratinocytes via His1 receptor (H1R). On the other hand, H4R is highly expressed on keratinocytes from patients with atopic dermatitis, and its stimulation induces keratinocyte proliferation and migration. Immature keratinocyte migration might represent a mechanism that contributes to the epidermal hyperplasia observed in patients with atopic dermatitis. H1R and H4R are also expressed in sensory neurons and are associated with scratching behaviors of mice. In addition to chemotaxis of Sema3A, various chemokines are associated with inducing and regulating keratinocyte migration [@bib4]. Among these chemokines, CCL16 is a His agonist that does not promote cell migratory activity [@bib5], and CCL17 is a non-His agonist that promotes cell migratory activity [@bib6]. To address the regulatory mechanism underlying kCer-induced chemotaxis on His-stressed cells, we investigated the effects of kCer on His receptors (HRs), especially H1R and H4R.

2. Materials and methods {#s0010}
========================

2.1. General {#s0015}
------------

The following materials were commercially obtained: kGlcCer was purchased from Nagara Scicence Co., Ltd. (Gifu, Japan); 2.5S mouse NGF (N100NF4325) from Alomone Labs; semaphorin 3A (Sema3A, 193-17051) from Wako Co.; C16Cer, C18Cer, and C24Cer from Avanti Polar Lipids; anti-pCofilin (Ser3) polyclonal antibody (pAb) from ABGENT (San Diego, CA); His, anti-CRMP2 pAb, and anti-phospho-CRMP2 pAb (pthr509) from Sigma-Aldrich; anti-GAPDH (3E12) monoclonal antibody (mAb) from Bioss (Woburn, MA); CCL16 (32-1861) from Abomics (San Diego, CA); and CCL17 (529-TR-025) from R&D Systems (Minneapolis, MN). Alkaline phosphatase (AP) activity was determined using an alkaline phosphatase (ALP) activity assay kit (LabAssay™) using *p*-nitrophenylphosphate (pNPP) as a substrate from Sigma.

kCer was prepared in our laboratory based on a published procedure [@bib2]. The tested lipid kCer (or other ceramides: C2Cer, C16Cer, C18Cer) was dissolved in 0.025% bovine serum albumin (BSA)/DMEM.

All experiments were performed with approval of the regulatory boards of Hokkaido University.

2.2. Cell culture and cell migration assay by chemical stimulation {#s0020}
------------------------------------------------------------------

HaCaT cells were cultured in regular Dulbecco\'s modified Eagle\'s Medium (DMEM) containing high Ca^2+^ (1.8 mM) supplemented with 10% fetal bovine serum (FBS), 10 mL/L penicillin-streptomycin solution (Wako Co., Osaka, Japan), and GlutaMAX™I (x100, Gibco; Thermo Fisher Scientific, Inc.) and maintained in an incubator under 5% CO~2~ at 37 °C. For the cell migration assay, cells were cultured for 48 h in low Ca^2+^ (0.02 mM)-DMEM containing 0.02 mM calcium chloride and 10% Ca^2+^-free FBS. To prepare Ca^2+^ free-FBS, FBS was incubated with Chelex 100 chelating resin (Bio-Rad, Berkeley, CA) with shaking for 4 h at 4 °C. Fresh resin was added and the preparation shaken overnight at 4 °C. The mixture was centrifuged and the supernatant used for Ca^2+^-free FBS.

The cell migration assay was performed using a trans-well chamber plate (6.5-mm D.I., 8.0 µm pore size, polycarbonate membrane; Transwell Permeable Supports 3422, Corning Inc., NY) as described in [Fig. S1B](#s0080){ref-type="sec"} and C. Cells that had been pretreated in low Ca2+ medium for 48 h as described above were seeded at a density of 2 × 10^4^ cells/well in the upper chamber supplemented with 200 μL of serum free-high Ca^2+^ medium, while 750 μL of complete medium containing 10% FBS with or without the tested reagents (Sema3A, kCer, His, CCL16, or CCL17) was added to the lower chamber compartment. After 48 h of incubation at 37 °C, the non-migrated cells in the upper chamber were gently removed with a cotton swab, and the cells that had moved to the lower compartment of the membrane were fixed with cold absolute methanol for 10 min and stained with GIEMSA\'S AZUR EOSIN Methylene Blue solution (109204, Merck, Darmstadt, Germany) as described [@bib6].

2.3. Western blot analysis {#s0025}
--------------------------

After treatment with kCer or other reagents, HaCaT cells were harvested for Western blot analysis. Cells were briefly lysed with RIPA Buffer (Wako Co., Osaka, Japan) supplemented with complete proteinase inhibitor (Roche, Basel, Switzerland) and PhosSTOP phosphatase inhibitor cocktail (Roche), and the protein concentrations of the supernatants were determined using the bicinchoninate protein assay kit (Nacalai Tesque, Kyoto, Japan). Equal amounts of protein (10 μg) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE, WAKO SuperSep™Ace, 5--20%), transferred to polyvinylidene fluoride (PVDF) membranes (Millipore Corp, MA, USA) using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (BioRad, Berkeley, CA), blocked with Blocking One (Nacalai Tesque) for 1 h, and incubated overnight at 4 °C with primary antibodies, anti-Cofilin (1:2000), anti-pCofilin (1:1000), or anti-GADPH (1:3000), diluted in 10% Blocking One solution with 0.05% Tween 20 and 50 mM Tris-buffered saline (TBST). The next day, each membrane was washed with TBST three times, 10 min each, and incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies (1:2000 to 1:4000) for 1 h at room temperature. The membrane was then treated with chemiluminescent reagent (Chemi-Lumi One Super, Nacalai Tesque, Inc., Japan). The antibody-bound protein bands were detected using the Syngene G: BOX Chemi XT4 fluorescence and chemiluminescence gel imaging system (Syngene, Bangalore, India). The relative intensities of developed bands were quantitated using JustTLC software (SWEDAY, Sodra, Sweden) and normalized to the loading control (GAPDH).

2.4. Receptor binding study using AP-Sema3A {#s0030}
-------------------------------------------

Alkaline phosphatase-fused Sema3A (AP-Sema3A) was used as a ligand for receptor binding assays. AP-Sema3A (chick) was a gift from Jonathan Raper (Addgene plasmid \# 29448)[@bib7]. Recombinant AP-Sema3A protein was expressed in HEK293 cells that were transiently transfected with an expression plasmid using a Lipofection Kit (ScreenFecT™A plus, Wako Co.). After 2 days of culturing in Opti-MEM, AP-Sema3A protein in the conditioned medium was concentrated, and the enzyme specific activity was determined by AP Activity Kit (LabAssay™ALP, Wako Co.) and SEMA3A ELISA Kit (ABIN1566604, Aviva Systems Biology, San Diego, CA). According to both assays, a ratio of relative AP activity units (APU, mmol/min/mg protein) of AP per Sema3A protein was calculated as 15.3 APU. For the HaCaT cell receptor binding assay, AP-Sema3A was used at a final concentration of 22.3 nM for 6 × 10^4^ cells per well of a 24-well microplate. After the microplate was incubated at 22 °C for 90 min, the wells were washed with HH-buffer (0.005%BSA/Hank\'s balanced buffer+20 mM HEPES buffer (pH 7.0)), followed by fixation with 3.7% formaldehyde/PBS solution. The fixation medium was exchanged with AP-buffer (100 mM NaCl + 5 mM MgCl~2~/50 mM Tris-HCl (pH 9.5)), and then incubated at 65 °C for 30 min. The wells were washed with HH-buffer and treated with a substrate solution of BCIP/NBT Phosphatase Substrate (1-Component, KPL, Gaithersburg, MD, USA). After the coloration reaction with AP-Sema3A, the dye was measured using Imaging-J (1.50 g). The ligand substitution experiment was performed using 22.3 nM AP-Sema3A together with kCer, kGlcCer, C16Cer, C18Cer, and C24Cer dissolved in 0.3% BSA.

2.5. TGFα-shedding assay {#s0035}
------------------------

The assay procedure was performed according to the method as described by Inoue et. al. [@bib8], [@bib9]. Before transfection, HEK293 T cells were seeded in a 12-well plate overnight (5 × 10^5^cells/mL, 1 mL/well). Each well was transfected in Lipofectamine solution containing plasmids (250 μL per well): a mixture of 125 μL OptiMEM with AP-TGFα (0.25 μg), hGPCR (H1R or H4R, 0.1 μg), and Gαq/il (for H4R, 0.05 μg) and 125 μL OptiMEM with LFA2000 (1.25 μL). After overnight incubation, the cells were detached from the wells and re-seeded in a 96-well plate and cultured for 30 min. His and other tested reagents (Sema3A, kCer, CCL16, or CCL17) were added and cultured for 1 h. The supernatant and cells were separated by plate centrifugation, and the AP activity in the supernatant and cells was determined using pNPP as the substrate and measuring the absorbance at 405 nm using the iMark™ microplate reader (Bio-Rad). The data represent the ratio of the AP activity in the supernatant to the total AP activity, expressed as a percentage.

2.6. Statistical analysis {#s0040}
-------------------------

The number (n) in each experimental condition is indicated in the figure legends. Data analysis was performed using the commercial program Prism 4.0 (GraphPad, San Diego, CA). When two experimental conditions were compared, statistical analysis was performed using a paired *t*-test. Otherwise, statistical analysis was performed using one-way ANOVA followed by Tukey\'s multiple comparison post-test and Dunnett\'s test. A *p* value less than 0.05 was considered significant. \* indicates significantly different results. Ranges of *p* values are indicated in the figure legends. NS indicates non-significant.

All experiments were performed with approval of the regulatory boards of Hokkaido University.

3. Results {#s0045}
==========

3.1. kCer inhibits the binding of AP-Sema3A to a cell surface receptor {#s0050}
----------------------------------------------------------------------

To examine whether kCer can associate with Sema3A binding to a cell surface receptor on HaCaT cells, the cells were incubated with AP-Sema3A in combination with non-labeled Sema3A or kCer. As shown in [Fig. 1](#f0005){ref-type="fig"}A and B, the binding of AP-Sema3A to cells was clearly attenuated by addition of 10--100 nM Sema3A or 10--100 μM kCer. The inhibitory effect of kCer on Sema3A binding to the cell surface receptor was clearly demonstrated, although the attenuating effect of the displacement was weaker than with Sema3A ([Fig. 1](#f0005){ref-type="fig"}A).Fig. 1Binding characteristics of Sema3A to cell surface receptors in HaCaT cells. **A:** Displacement profile of kCer on AP-Sema3A binding to cell surface receptors. Cells were cultured in a 24-well microplate and treated with 15.3 APU of 22.3 nM AP-Sema3A in the presence of Sema3A (10--100 nM) (upper graph) or kCer (10--100 μM) (lower graph). Cells were washed and incubated at 65 °C for 30 min, and the remaining AP activity was measured using BCIP/NBT Phosphatase Substrate and Imaging-J software. Data are shown as the means ± SD (n = 4). **B:** AP-Sema3A binding to cells in the presence of Sema3A (0, 10, 50, and 100 nM) or kCer (0, 10, 50, 100 μM). **C:** Displacement profile of AP-Sema3A binding by Sema3A (50 nM), kCer, kGlcCer, C16Cer, C18Cer, and C24Cer (50 μM, respectively).Fig. 1

We evaluated the displacement reactivity at 50 μM of kCer and other ceramides (kGlcCer, C16Cer, C18Cer, and C24Cer) for AP-Sema3A binding to the cell surface receptor. As compared to kCer (50 μM) and Sema3A (50 nM), the other ceramides did not show any effect on AP-Sema3A binding to the cell surface receptor ([Fig. 1](#f0005){ref-type="fig"}C).

3.2. Effect of Sema3A, kCer, His, and chemokines on HaCaT cell migration {#s0055}
------------------------------------------------------------------------

To examine the effect of kCer or Sema3A on HaCaT cell migration, cells were exposed to Sema3A (1--200 nM) or kCer (10--100 μM) ([Fig. 2](#f0010){ref-type="fig"}). As shown in [Fig. 2](#f0010){ref-type="fig"}A and B, increasing the concentration of Sema3A and kCer resulted in an attenuating effect on cell migration by complete serum-containing medium. On the other hand, His induced a stimulating effect on cell migration at low concentration (0.1--1.0 μM), but showed a suppressing effect at high concentration (10--100 μM). The chemokine CCL16 showed no effect but CCL17 showed a stimulating effect on cell migration.Fig. 2Cell migration profile of HaCaT cells. Media containing complete sera induced migration of HaCaT cells in a 24-well chamber plate assay. Cell migration activity was determined quantitatively using Image-J after GIEMSA\'S AZUR EOSIN Methylene Blue-staining of transwell filter membrane. **A:** The following were added to the bottom wells of a 24-well Boyden chamber: No addition (None); Sema3A (10 nM); kCer (25 μM); His (1 μM); CCL16 (10 nM, His agonist for H4R); and CCL17 (10 nM, non-His agonist). **B:** Cell migration was quantitated as % of control (no addition). Data are shown as the means ± SD (n = 4). *\*P* \< 0.05, *\*\*P* \< 0.001 vs. vehicle-treated control.Fig. 2

To examine the combined effect of kCer (or Sema3A) and His (or CCL16 or CCL17), cells were exposed to His(1 μM), CCL16(1 nM), or CCL17(1 nM) in the presence or absence of kCer (25 μM) or Sema3A (100 nM) ([Fig. 3](#f0015){ref-type="fig"}A). As shown in [Fig. 3](#f0015){ref-type="fig"}B, Sema3A remarkably decreased the level of His- and CCL-17-induced stimulation of cell migration. kCer showed a similar effect ([Fig. 3](#f0015){ref-type="fig"}C). CCL16 showed no effect on the cell migration activity, and did not affect the inhibitory activity of kCer and Sema3A (compare the rightmost columns of [Fig. 3](#f0015){ref-type="fig"}B and C to the control on the left).Fig. 3Combined effect of Sema3A or kCer with His or CCL chemokines (CCL16 or CCL17) on cell migration. **A:** Migration of HaCaT cells stimulated by no addition (None), Sema3A (100 nM), or kCer (25 μM) plus His (1 μM), CCL16 (10 nM), or CCL17 (10 nM). **B:** Effect of 100 nM Sema3A on cell migration by no other addition (None), 1 μM His, 10 nM CCL16 or 10 nM CCL17. **C:** Effect of 100 μM kCer on cell migration by no other addition (None), 1 μM His, 10 nM CCL16 or 10 nM CCL17. Cell migration was quantitated as % of control (no addition).Data are shown as the means ± SD (n = 4). *\*P* \< 0.05.Fig. 3

3.3. Effect on ligand activation of H1R and H4R by kCer {#s0060}
-------------------------------------------------------

To examine whether kCer (or Sema3A) can activate H1R or H4R by a hGPCR activation manner, we used a TGFα-shedding assay ([Fig. S2](#s0080){ref-type="sec"}). As shown in [Fig. S2](#s0080){ref-type="sec"}B, C, F, and G, neither kCer nor Sema3A showed any response of TGFα activity with H1R or H4R. On the other hand, CCL16 showed an increasing response for H4R activation, but no response for H1R ([Fig. S2](#s0080){ref-type="sec"}D and H). His-induced H1R and H4R activation was not influenced by kCer or Sema3A ([Fig. S2](#s0080){ref-type="sec"}I, J, M, and N). CCL17 is not a ligand of H1R and H4R and showed no response to the His-induced activation ([Fig. S2L](#s0080){ref-type="sec"} and P). On the other hand, specific inhibitors, pyrilamine for H1R and thioperamide for H4R, showed dose-dependent inhibitory responses to His-induced H1R and H4R activation, respectively ([Fig. S2](#s0080){ref-type="sec"}K and O).

3.4. Cofilin phosphorylation {#s0065}
----------------------------

NGF treatment induced CRMP2 production in PC12 cells ([Fig. S3](#s0080){ref-type="sec"}A) [@bib2], and kCer-induced CRMP2 phosphorylation via binding to Sema3A-receptor was also demonstrated in PC12 cells [@bib10]To determine if kCer also induced CRMP2 phosphorylation in HaCaT cells, the cells were treated with 100 ng/mL NGF for 24 or 48 h and analyzed by Western blot as previously published [@bib2]. As shown in [Fig. S3](#s0080){ref-type="sec"}B, treatment with NGF did not induce CRMP2 expression and phosphorylation in HaCaT cells

Alternatively, we examined NGF-induced Cofilin expression and phosphorylation in HaCAT cells. Total Cofilin (t-Cofilin) and phosphorylated-Cofilin (p-Cofilin) were expressed in HaCaT cells. There was no effect 0, 24, and 48 h after NGF treatment ([Fig. 4](#f0020){ref-type="fig"}A). Treatment with kCer (50 μM) or Sema3A (100 nM) for 0, 30, or 60 min in the absence of NGF showed no effect on t-Cofilin and p-Cofilin ([Fig. 4](#f0020){ref-type="fig"}B). However, p-Cofilin was elevated 30--60 min after kCer or Sema3A treatment as compared to untreated cells, as shown in [Fig. 4](#f0020){ref-type="fig"}C and D.Fig. 4Effect of Cofilin phosphorylation of kCer. HaCaT cells (4 × 10^5^) were cultured overnight in a 6-well culture plate with low Ca^2+^ (0.02 mM) DMEM containing 10% Ca^2+^-free FBS. After washing with high Ca^2+^ (1.8 mM) DMEM, cells were incubated with high Ca^2+-^DMEM containing 10% FBS for the indicated times (A: 0, 24, and 48 h; B: C, D: 0, 30, and 60 min). A and B: No addition. C: 50 μM kCer added. D: 100 nM kCer added. Bars represent amounts of cofilin relative to GAPDH. Data are shown as the means ± SD (n = 4). *\*P* \< 0.05, *\*\*P* \< 0.001.Fig. 4

4. Discussion {#s0070}
=============

In the peripheral nervous system and epidermis, Sema3A regulates itch sensations from nerve fiber extensions of sensory neurons by reversing NGF activity [@bib11], [@bib12]. At the cell surface, Sema3A forms a hetero- complex with neuropilin1 (Nrp1), and recruits plexin A1 (PlexA), thus enabling signal-transducing activity [@bib13], [@bib14]. Previously, we demonstrated that kCer directly interacts with Nrp1, which activates the Sema3A pathway, causing CRMP2 phosphorylation downstream of Sema3A. Nrp1 is also expressed as a Sema3A receptor by keratinocytes in vitro and in vivo [@bib15]. We investigated the binding of kCer or Sema3A to Nrp1 on the cell surface of keratinocytes by the use of AP-Sema3A and demonstrated that Sema3A could displace AP-labeled Sema3A (AP-Sema3A) ([Fig. 1](#f0005){ref-type="fig"}). As shown in [Fig. 1](#f0005){ref-type="fig"}C, kCer could also displace the AP-Sema3A, while kGlcCer and other ceramides could not. This result showed that kCer is a weak agonist of Sema3A as also shown in our previous study with PC12 cells [@bib10]. Unexpectedly, NGF did not induce CRMP2 production and phosphorylation by Sema3A in HaCaT cells ([Fig. S3](#s0080){ref-type="sec"}B), as it did in PC12 cells as previously reported by us [@bib2]. However, Cofilin expression and phosphorylation occurred in unstimulated HaCaT cells, and downstream activation of the Sema3A pathway by Sema3A or kCer induced phosphorylation of Cofilin, resulting in an increased level of p-Cofilin ([Fig. 4](#f0020){ref-type="fig"}C and D). Sema3A is known to inhibit cell migration of HaCaT cells [@bib16]. Nrp1 expression was increased with normal keratinocyte differentiation and migration in the epidermis, resulting in Sema3A-induced inhibition of cell migration. In the present study kCer was demonstrated to work on Nrp1of HaCaT cell, resulting in signaling pathway of Sema3A as shown in the schematic presentation of [Fig. 5](#f0025){ref-type="fig"}.Fig. 5Proposed mechanism for kCer acting as a Sema3A-like ligand. Sema3A binding: Sema3A binds to Nrp1, recruiting a monomer from an inactive PlexA dimer, resulting in the formation of a hetero-pentameric complex of Sema3A, Nrp1 dimer, and PlexA. Signaling pathway downstream molecule of the Sema3A, Cofilin is phosphorylated, resulting in suppression of actin turnover, causing an inhibition of cell migration. kCer also binds as a Sema3A-like ligand to Nrp1 without Sema3A and forms of the receptor complex to induces an inhibitory effect on cell migration.Fig. 5

His treatment induces proliferation [@bib17] but suppresses epidermal keratinocyte differentiation [@bib3]. In human in vitro keratinocyte cultures, it was reported [@bib18] that His reduced keratinocyte differentiation in an H1R-dependent manner, while experiments with His receptor agonists and antagonists showed no effect on keratinocyte differentiation. There is also evidence that H4R knockout mice show reduced epidermal thickness and decreased in vitro proliferation of keratinocytes [@bib18]. Keratinocyte proliferation can be induced in a paracrine or autocrine manner by various mediators. Since His is mainly secreted by mast cells, it regulates keratinocyte proliferation in a paracrine manner, if we assume that His directly affects keratinocyte proliferation. It is assumed that His and Sema3A must be processed by different signaling mechanisms, and keratinocyte migration effects are the outcome of the different upstream cell signaling pathways. We showed that 0.1--1 μM His enhanced the cell migration of HaCaT cells in high Ca^2+^ serum medium ([Fig. 2](#f0010){ref-type="fig"}B). This enhancement effect is thought to occur in immature cells in low Ca^2+^ medium (data not shown). To examine the inhibitory mechanism of kCer or Sema3A on HaCaT cell migration, HaCaT cells were exposed to His and the chemokines CCL16 (His agonist with absence of cell migratory activity) [@bib5] and CCL17 (non-His agonist with presence of cell migratory activity) [@bib6].

As expected, cell migration was not affected in the presence of CCL16 but was enhanced in the presence of CCL17 ([Fig. 2](#f0010){ref-type="fig"}B). As shown in [Fig. 3](#f0015){ref-type="fig"}B and C, His-induced stimulation of cell migration was inhibited by Sema3A or kCer, which also inhibited CCL17-induced stimulation, whereas Sema3A or kCer inhibited cell migration independently of CCL16. An alternative possibility is that kCer interacts with H1R or H4R directly and transduces any signal downstream of the His signaling pathway. The interaction of kCer or Sema3A with H1R or H4R was addressed by testing ligand activation in the TGFα-shedding assay. As shown in [Fig. S2](#s0080){ref-type="sec"}, kCer did not react with H1R or H4R.

kCer is not associated with the His-H1R (or H4R) binding that occurs at the cell surface in the His signaling pathway, but it remains unknown whether kCer\'s inhibitory effect on His-induced stimulation of cell migration occurred downstream of the His signaling pathway.
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